We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Raised guidance is always a welcome development for investors, reflecting improving business trends and management confidence in the outlook. The positivity can also fuel bullish earnings estimate revisions, a major driver of share outperformance.
Recently, several notable companies, including BWX Technologies (BWXT - Free Report) , Johnson & Johnson (JNJ - Free Report) , and UnitedHealth Group (UNH - Free Report) , have raised their FY26 outlooks following solid quarterly results. Let's take a closer look at each.
BWX Technologies Sees Nuclear Strength
BWX Technologies provides nuclear components, fuel, and specialized services for government defense programs and commercial nuclear power markets.
The company posted solid results in its latest release, with revenue climbing 18% YoY to $901.6 million. Commercial Operations sales were particularly strong, jumping 72% to $302.5 million.
The favorable performance led management to raise its FY26 adjusted EPS guidance to $4.70–$4.80 per share, up from the prior $4.60–$4.75 range. It also raised its free cash flow outlook to $345–$360 million, reflecting an additional positive.
Importantly, the company's commercial nuclear business continues to benefit from growing demand, with its expanded manufacturing footprint also supporting the outlook.
Johnson & Johnson Raises Outlook
Johnson & Johnson delivered another solid quarterly report, with sales climbing 5.9% YoY to $25.4 billion. Its Innovative Medicine business was a major bright spot, posting 7.7% sales growth to roughly $16.8 billion.
The favorable results led management to raise its FY26 adjusted EPS outlook by $0.06 at the midpoint to $11.10 per share, with expected annual sales of $101.2 billion at the midpoint also reflecting an increase.
Continued strength across its pharmaceutical portfolio, particularly products such as TREMFYA and CAPLYTA, has been a major positive. Still, MedTech sales growth remained more modest at 2.5%, reflecting some softness.
UnitedHealth Group Sees Improving Trends
UnitedHealth Group has faced a challenging operating environment over recent years, particularly concerning elevated medical costs. But its latest quarterly results showed nice improvement, giving investors a sigh of relief for now.
The company's medical care ratio fell to 88.4% from 89.9% in the same period last year, reflecting improving cost trends. Operating earnings also climbed significantly to $6.6 billion from $4.3 billion.
The improved performance led management to raise its FY26 adjusted EPS outlook to at least $20.50 per share, above the prior $19.50–$20.00 range.
While membership declines remain a challenge, the improved cost picture and higher earnings outlook suggest its turnaround efforts are gaining traction.
Bottom Line
Raised guidance reflects a positive development for BWX Technologies (BWXT - Free Report) , Johnson & Johnson (JNJ - Free Report) , and UnitedHealth Group (UNH - Free Report) , with all three seeing improving business trends.
View the Zacks #1 Rank List
3 Companies Raising Guidance This Earnings Season
Raised guidance is always a welcome development for investors, reflecting improving business trends and management confidence in the outlook. The positivity can also fuel bullish earnings estimate revisions, a major driver of share outperformance.
Recently, several notable companies, including BWX Technologies (BWXT - Free Report) , Johnson & Johnson (JNJ - Free Report) , and UnitedHealth Group (UNH - Free Report) , have raised their FY26 outlooks following solid quarterly results. Let's take a closer look at each.
BWX Technologies Sees Nuclear Strength
BWX Technologies provides nuclear components, fuel, and specialized services for government defense programs and commercial nuclear power markets.
The company posted solid results in its latest release, with revenue climbing 18% YoY to $901.6 million. Commercial Operations sales were particularly strong, jumping 72% to $302.5 million.
The favorable performance led management to raise its FY26 adjusted EPS guidance to $4.70–$4.80 per share, up from the prior $4.60–$4.75 range. It also raised its free cash flow outlook to $345–$360 million, reflecting an additional positive.
Importantly, the company's commercial nuclear business continues to benefit from growing demand, with its expanded manufacturing footprint also supporting the outlook.
Johnson & Johnson Raises Outlook
Johnson & Johnson delivered another solid quarterly report, with sales climbing 5.9% YoY to $25.4 billion. Its Innovative Medicine business was a major bright spot, posting 7.7% sales growth to roughly $16.8 billion.
The favorable results led management to raise its FY26 adjusted EPS outlook by $0.06 at the midpoint to $11.10 per share, with expected annual sales of $101.2 billion at the midpoint also reflecting an increase.
Continued strength across its pharmaceutical portfolio, particularly products such as TREMFYA and CAPLYTA, has been a major positive. Still, MedTech sales growth remained more modest at 2.5%, reflecting some softness.
UnitedHealth Group Sees Improving Trends
UnitedHealth Group has faced a challenging operating environment over recent years, particularly concerning elevated medical costs. But its latest quarterly results showed nice improvement, giving investors a sigh of relief for now.
The company's medical care ratio fell to 88.4% from 89.9% in the same period last year, reflecting improving cost trends. Operating earnings also climbed significantly to $6.6 billion from $4.3 billion.
The improved performance led management to raise its FY26 adjusted EPS outlook to at least $20.50 per share, above the prior $19.50–$20.00 range.
While membership declines remain a challenge, the improved cost picture and higher earnings outlook suggest its turnaround efforts are gaining traction.
Bottom Line
Raised guidance reflects a positive development for BWX Technologies (BWXT - Free Report) , Johnson & Johnson (JNJ - Free Report) , and UnitedHealth Group (UNH - Free Report) , with all three seeing improving business trends.